1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Erectile Dysfunction Market - Global Outlook and Forecast 2018-2023

Erectile Dysfunction Market - Global Outlook and Forecast 2018-2023

  • February 2018
  • 182 pages
  • ID: 5311923

Summary

Table of Contents

Search Inside

This market research report on the erectile dysfunction market offers analysis on market size and forecast, market share, industry trends, growth drivers, and vendor analysis. The study also includes insights on segmentation by therapy type (drug therapies and device therapies) and geography (APAC, Europe, Latin America, MEA, and North America).

Erectile Dysfunction Market - Overview
Increasing disease awareness, growing patient willingness to seek medical assistance for disease management, and the increasing presence of favorable guidelines are driving the growth of the erectile dysfunction market. The three most popular erectile dysfunction drugs that are available in the market are ED oral drugs, Viagra, Cialis, and Levitra. The global erectile dysfunction market is also witnessing a rising demand for low-cost generic drugs, especially in the APAC countries such as Indian and China. The US and Europe are the main revenue contributors in the global erectile dysfunction market. The growing number of chronic medical conditions such as diabetes, hypertension, dyslipidemia, and coronary heart disease across the globe is also increasing the number of erectile dysfunction patients and boosting the demand for therapeutics in the global market. The increasing investments in R&D for the development of new drugs and clinical trials will augment the growth of the erectile dysfunction market.

The growing awareness of male sexual health conditions and the increasing healthcare spending for sexual wellness, especially in the APAC region will propel the development of the erectile dysfunction market. The introduction of innovative drug therapy will have a positive impact on the growth of the erectile dysfunction market. The erectile dysfunction market is expected to generate revenue of $4.25 billion during the forecast period.

Erectile Dysfunction Market - Dynamics
Increase in strategic agreements and consolidations among the leading vendors to expand their services or product portfolios is likely to contribute to the growth of the global erectile dysfunction market. Mergers and acquisitions will allow players to gain competitive advantage with a wide product portfolio and vast geographical reach, thereby driving the growth and profitability of vendors in the erectile dysfunction market. These strategic consolidations and mergers will help prominent companies to expand their businesses in emerging markets and widen their distribution networks to attract a large consumer base. For instance, a licensing agreement between A. Menarini Asia-Pacific and Mitsubishi Tanabe Pharma was signed to commercialize and promote avanafil in China, Hong Kong, Taiwan, Macao, the Philippines, Singapore, Indonesia, Malaysia, Thailand, and Vietnam.

Erectile Dysfunction Market Segmentation
This market research report includes a detailed segmentation of the market by therapy and geography.

Erectile Dysfunction Market – By Therapy Type
Drugs therapy type to dominate the erectile dysfunction market during the forecast period

The erectile dysfunction market by therapy type is classified into drugs and devices. The drugs therapy segment dominated the erectile dysfunction market, accounting for close to 89% of the total market share in 2017 and is expected to generate revenue of about $3,487.41 million during the forecast period. Preferability for needle-free penile injection kits and increase in disease awareness will fuel the growth of this drug segment in the erectile dysfunction market. The market for other drug therapy types, topical agents, intraurethral suppositories, and intracavernosal injections is expected to grow at a moderate pace over the next few years. The erectile dysfunction market will also observe a negative growth due to the patent expiration of generic versions of key oral drugs Viagra, Cialis, and Levitra during the forecast period.

Erectile Dysfunction Market – By Geography
North America to occupy the largest market share in the erectile dysfunction market during the forecast period

The geographical segment in the erectile dysfunction market is divided into APAC, Europe, Latin America, MEA, and North America. North America dominated the global erectile dysfunction market, occupying more than 43% of the total market share in 2017 and is expected to generate the revenue of $1,832.82 million by 2023. Factors such as better access to ED treatments and reimbursement coverage for high post penile implant surgeries is fueling the growth of the erectile dysfunction market in North America. The US accounts for more than 90% of the total market share in the erectile dysfunction market in North America. The high uptake and access to both prescription and OTC devices in North America is attributing the revenue of the erectile dysfunction market in this region. Moreover, increasing penile implantation surgical procedures, growing e-commerce sales of penile erection devices, and rising preference for advanced non-invasive devices will have a positive impact on the growth of the erectile dysfunction market in North America.

Key Countries Profiled
The key countries profiled in the report are:
• US
• Canada
• Germany
• UK
• France
• Italy
• Spain
• Japan
• India
• China
• Australia
• Brazil
• Mexico

Key Vendor Analysis
The erectile dysfunction market is oligopolistic, as a limited number of major players occupies the predominant market share. A minority of the market share has occupied by a surfeit of specialty and generic drug companies. The strategic initiatives adopted by the leading and other prominent companies will intensify the competition in the erectile dysfunction market during the forecast period. The leading companies are focusing on leveraging their strengths to diversify their product portfolios and increase their global market presence. The entry of new players and the introduction of innovative therapeutics will increase the level of competition in the global erectile dysfunction market during the forecast period.

The major vendors in the global market are:
• Bayer AG
• Eli Lilly and Company
• VIVUS Inc.
• Pfizer
• Boston Scientific Corp.
• Coloplast A/S

Other prominent vendors include Apricus Biosciences, Inc, Endo International plc, Futura Medical, Premedon, Teva Pharmaceutical Industries Limited (Teva), Zephyr Surgical Implants (ZSI), Augusta Medical Systems LLC (Augusta Medical), Post-T-Vac Medical, Bonro Medical, Cristalia Produtos Quimicos Farmaceuticos Ltd, and SK Chemicals.

Key market insights include

1. The analysis of erectile dysfunction market provides market size and growth rate for the forecast period 2018-2023.
2. It offers comprehensive insights on current industry trends, trend forecast, and growth drivers about the erectile dysfunction market.
3. The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities.
4. It offers a complete overview of market segments and the regional outlook for erectile dysfunction market.
5. The report offers a detailed overview of the vendor landscape, competitive analysis, and key market strategies to gain competitive advantage.

Report Sanapshot

According to the latest industry analysis by Arizton, the size of the global erectile dysfunction market is expected to reach $4.25 billion by 2023. The market research report provides in-depth market analysis and segmental analysis of the global erectile dysfunction market by product, distribution channel, material, and geography.

The global erectile dysfunction market is driven by the wide availability of treatment options oral therapies and newly emergent low-intensity extra-corporeal shockwave therapy. The introduction of other conventional therapies such as oral, topical, penile injectables, and vacuum constriction devices will also create opportunities for vendors in the global erectile dysfunction market.

Base Year: 2017
Forecast Year: 2018–2023

The study considers the present scenario of the global erectile dysfunction market and its market dynamics for the period 2018'2023. The study covers a detailed overview of various market growth enablers, restraints, and trends. It covers both the demand and supply sides of the market. The study also profiles and analyzes the top six leading companies and 12 other prominent companies operating in the market.

Major Vendors in the Erectile Dysfunction Market
• Bayer AG
o Key Financial Highlights
o Strength Assessment
o Strategy Assessment
o Opportunity Assessment
• Eli Lilly and Company
• VIVUS Inc.
• Pfizer
• Boston Scientific Corp.
• Coloplast A/S

Prominent Players in the Erectile Dysfunction Market
• Apricus Biosciences Inc.
o Strength Assessment
o Strategy Assessment
o Opportunity Assessment
• Endo International plc
• Futura Medical
• Premedon
• Teva Pharmaceutical Industries Limited (Teva)
• Zephyr Surgical Implants (ZSI)
• Augusta Medical Systems LLC (Augusta Medical)
• Post-T-Vac Medical
• Bonro Medical
• Cristalia Produtos Quimicos Farmaceuticos Ltd.
• SK Chemicals

Market Segmentation by Therapy Type
• ED Drugs
o Oral Therapies
o Topical Therapies
o Intrauretheral suppositories & Penile injection therapies
• ED Devices
o Vacuum erection devices
o Penile Implants
o Others

Market Segmentation by Geography
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
• APAC
o Japan
o India
o China
o Australia
• Latin America
o Brazil
o Mexico
• MEA

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Erectile Dysfunction R&D Pipeline Analysis Report, H2-2018

Erectile Dysfunction R&D Pipeline Analysis Report, H2-2018

  • $ 2200
  • August 2018

Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studiesErectile Dysfunction Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information ...

Erectile Dysfunction Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2024

Erectile Dysfunction Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2024

  • $ 4795
  • November 2018

The report on the global erectile dysfunction drugs market provides qualitative and quantitative analysis for the period from 2016 to 2024.The report predicts the global erectile dysfunction drugs market ...

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2018

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2018

  • $ 3500
  • November 2018

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2018SummaryProtein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 ...


ref:plp2018

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on